Remifentanil: A review of its analgesic and sedative use in the Intensive Care Unit

Drugs

Volumn 66, Issue 3, 2006, Pages 365-385

  Battershill, Anna J ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Analgesia; Intensive care; Pharmacodynamics; Pharmacokinetics; Remifentanil; Sedation; Therapeutic use

Indexed keywords

ALFENTANIL; FENTANYL; ISOFLURANE; MIDAZOLAM; MORPHINE; PLACEBO; PROPOFOL; REMIFENTANIL; SUFENTANIL; HYPNOTIC SEDATIVE AGENT; NARCOTIC ANALGESIC AGENT; PIPERIDINE DERIVATIVE;

ANALGESIA; ANALGESIC ACTIVITY; ANESTHESIA INDUCTION; ARTIFICIAL VENTILATION; BLOOD PRESSURE; BRADYCARDIA; BRAIN INJURY; BRAIN PERFUSION; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; EXTUBATION; FEVER; HEART ATRIUM FIBRILLATION; HEART RATE; HEMODYNAMICS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOTENSION; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRACRANIAL PRESSURE; METABOLITE; NAUSEA; PAIN; REVIEW; SEDATION; SEPTIC SHOCK; TRACHEOBRONCHIAL TOILET; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; VOMITING; AGE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; PAIN ASSESSMENT; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; ANALGESICS, OPIOID; DRUG ADMINISTRATION SCHEDULE; FENTANYL; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE UNITS; MORPHINE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PIPERIDINES; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RESPIRATION, ARTIFICIAL;

EID: 33746060562     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666030-00013     Document Type: Review

References (79)

1. Gravel NR, Searle NR, Sahab PG, et al. Sedation in critically ill patients: practical recommendations. CNS Drugs 1999 Jan; 11 (1): 9-22
2. Park G. Remifentanil in the ICU: a new approach to patient care. Curr Anaesthes Crit Care 2002; 13 (6): 313-20
3. Scott LJ, Perry CM. Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs 2005; 65 (13): 1793-823
4. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal. Clin Pharmacokinet 1995 Aug; 29 (2): 80-94
5. Cox EH, Langemeijer MWE, Gubbens-Stibbe JM, et al. The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology 1999 Feb; 90 (2): 535-44
6. Hoke JF, Cunningham F, James MK, et al. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther 1997; 281 (1): 226-32
7. Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 1993 Nov; 77 (5): 1031-40
8. Mason P. Remifentanil. Intensive Crit Care Nurs 2002; 18: 355-7
9. Hoffman WE, Cunningham F, James MK, et al. Effects of remifentanil, a new short-acting opioid, on cerebral blood flow, brain electrical activity, and intracranial pressure in dogs anesthetized with isoflurane and nitrous oxide. Anesthesiology 1993 Jul; 79 (1): 107-13
10. Breen D, Wilmer A, Bodenham A, et al. Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care 2004 Feb; 8 (1): R21-30
11. Breen D, Karabinis A, Malbrain M, et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial. Crit Care 2005 Jun; 9 (3): R200-10
12. Muellejans B, López A, Cross MH, et al. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial. Crit Care 2004 Feb; 8 (1): R1-11
13. Chinachoti T, Kessler P, Kirkham A, et al. Remifentanil vs morphine for patients in intensive care unit who need short-term mechanical ventilation. J Med Assoc Thai 2002 Sep; 85 (Suppl. 3): 848-57
14. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial. Crit Care 2004 Aug; 8 (4): R268-80
15. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanil on intracranial pressure and cerebral blood flow velocity in patients with head trauma. Acta Anaesthesiol Scand 2004 Apr; 48 (4): 396-9
16. Reeker W, Hanel F, Detsch O, et al. The effects of remifentanil on systemic hemodynamic and EEG responses during endotracheal suctioning in ICU patients [abstract no. A203]. Anesthesiology 1997 Sep; 87 (3 Suppl.)
17. Cavaliere F, Antonelli M, Arcangeli A, et al. A low-dose remifentanil infusion is well tolerated for sedation in mechanically ventilated, critically ill patients. Can J Anesth 2002 Dec; 49 (10): 1088-94
18. Dahaba AA, Grabner T, Rehak PH, et al. Remifentanil versus morphine analgesia and sedation for mechanically ventilated critically ill patients: a randomized double blind study. Anesthesiology 2004 Sep; 101 (3): 640-6
19. Leone M, Albanèse J, Viviand X, et al. The effects of remifentanil on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients. Anesth Analg 2004 Oct; 99 (4): 1193-8
20. Glass PSA, Iselin-Chaves IA, Goodman D, et al. Determination of the potency of remifentanil compared with alfentanil using ventilatory depression as the measure of opioid effect. Anesthesiology 1999 Jun; 90 (6): 1556-63
21. Black ML, Hill JL, Zacny JP. Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers. Anesthesiology 1999 Mar; 90 (3): 718-26
22. Egan TD. Pharmacokinetics and pharmacodynamics of remifentanil: an update in the year 2000. Curr Opin Anaesthesiol 2000; 13 (4): 449-55
23. James MK, Feldman PL, Schuster SV, et al. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther 1991; 259 (2): 712-8
24. Amin HM, Sopchak AM, Esposito BF, et al. Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharmacol Exp Ther 1995; 274 (1): 34-9
25. Gustorff B, Felleiter P, Nahlik G, et al. The effect of remifentanil on the heat pain threshold in volunteers. Anesth Analg 2001; 92: 369-74
26. Petersen KL, Jones B, Segredo V, et al. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat-capsaicin sensitization model in healthy volunteers. Anesthesiology 2001 Jan; 94 (1): 15-20
27. Curatolo M, Petersen-Felix S, Gerber A, et al. Remifentanil inhibits muscular more than cutaneous pain in humans. Br J Anaesth 2000; 85 (4): 529-32
28. Lötsch J, Angst MS. The μ-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans. Pain 2003; 102: 151-61
29. Shinohara K, Aono H, Unruh GK, et al. Suppressive effects of remifentanil on hemodynamics in baro-denervated rabbits. Can J Anesth 2000; 47 (4): 361-6
30. James MK, Vuong A, Grizzle MK, et al. Hemodynamic effects of GI 87084B, an ultra-short acting mu-opioid analgesic, in anesthetized dogs. J Pharmacol Exp Ther 1992; 263 (1): 84-91
31. Sebel PS, Hoke JF, Westmoreland C, et al. Histamine concentrations and hemodynamic responses after remifentanil. Anesth Analg 1995 May; 80 (5): 990-3
32. Kazmaier S, Hanekop G-G, Buhre W, et al. Myocardial consequences of remifentanil in patients with coronary artery disease. Br J Anaesth 2000 May; 84 (5): 578-83
33. Noseir RK, Ficke DJ, Kundu A, et al. Sympathetic and vascular consequences from remifentanil in humans. Anesth Analg 2003; 96: 1645-50
34. Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect of a remifentanil bolus on ventilatory control. Anesthesiology 2000 Feb; 92 (2): 393-8
35. Lorenz IH, Kolbitsch C, Schocke M, et al. Low-dose remifentanil increases regional cerebral blood flow and regional cerebral blood volume, but decreases regional mean transit time and regional cerebrovascular resistance in volunteers. Br J Anaesth 2000 Aug; 85 (2): 199-204
36. Paris A, Scholz J, von Knobelsdorff G, et al. The effect of remifentanil on cerebral blood flow velocity. Anesth Analg 1998 Sep; 87: 569-73
37. Klimscha W, Ullrich R, Nasel C, et al. High-dose remifentanil does not impair cerebrovascular carbon dioxide reactivity in healthy male volunteers. Anesthesiology 2003 Oct; 99 (4): 834-40
38. 2O) anesthesia. Anesthesiology 1998 Aug; 89 (2): 358-63
39. Baker KZ, Ostapkovich N, Sisti MB, et al. Intact cerebral blood flow reactivity during remifentanil/nitrous oxide anesthesia. J Neurosurg Anesthesiol 1997; 9 (2): 134-40
40. Lorenz IH, Kolbitsch C, Hörmann C, et al. The effects of remifentanil on cerebral capacity in awake volunteers. Anesth Analg 2000 Mar; 90 (3): 609-13
41. Nieuwenhuijs DJF, Olofsen E, Romberg RR, et al. Response surface modeling of remifentanil-propofol interaction in cardiorespiratory control and bispectral index. Anesthesiology 2003 Feb; 98 (2): 312-22
42. Koitabashi T, Johansen JW, Sebel PS. Remifentanil dose/ electroencephalogram bispectral response during combined propofol/regional anesthesia. Anesth Analg 2002; 94: 1530-3
43. Kan RE, Hughes SC, Rosen MA, et al. Intravenous remifentanil: placental transfer, maternal and neonatal effects. Anesthesiology 1998 Jun; 88 (6): 1467-74
44. Pitsiu M, Wilmer A, Bodenham A, et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth 2004 Apr; 92 (4): 493-503
45. GlaxoSmithKline UK. Ultiva injection: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Jul 18]
46. Dahaba AA, Oettl K, von Klobucar F, et al. End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. Can J Anaesth 2002 Apr; 49 (4): 369-74
47. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996 Apr; 84 (4): 812-20
48. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993 Nov; 79 (5): 893-903
49. Bouillon T, Bruhn J, Radu-Radulescu L, et al. Non-steady state analysis of the pharmacokinetic interaction between propofol and remifentanil. Anesthesiology 2002 Dec; 97 (6): 1350-62
50. Ross AK, Davis PJ, Dear GDL, et al. Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. Anesth Analg 2001; 93: 1393-401
51. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997 Jan; 86 (1): 10-23
52. Wilhelm W, Dorscheid E, Schlaich N, et al. Remifentanil zur analgosedierung von intensivpatienten. Anaesthesist 1999; 48: 625-9
53. Royston D, Kirkham A, Adt M, et al. Extubation following CABG using remifentanil based total intravenous anesthesia (TIVA) [abstract no. A239]. Anesthesiology 1996 Sep; 83 (3A Suppl.)
54. Morrison L, Binning AR, Bodenham AR, et al. Remifentanil versus fentanyl in providing optimal sedation in post-surgical ICU patients: preliminary results [abstract no. 354]. 13th Annual Congress of the European Society of Intensive Care Medicine; 2000 Oct 1-4; Rome
55. Davidson A, Skolka M, Kessler P, et al. Remifentanil vs. morphine for the provision of optimal sedation in ICU patients: preliminary results [abstract no. A-405]. Eur J Anaesthesiol 2001; 18 Suppl. 21: 114-5
56. Howie MB, Cheng D, Newman MF, et al. A randomized double-blinded multicenter comparison of remifentanil versus fentanyl when combined with isoflurane/propofol for early extubation in coronary artery bypass graft surgery. Anesth Analg 2001 May; 92 (5): 1084-93
57. Matthey T, Schill M, Muellejans B. Earlier discharge from ICU with remifentanil/propofol versus fentanyl/midazolam [abstract]. Intensive Care Med 2004; 30 Suppl. 1: 174
58. Soltesz S, Biedler A, Silomon M, et al. Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. Br J Anaesth 2001 Jun; 86 (6): 763-8
59. Baillard C, Cohen Y, Le Toumelin P, et al. Rémifentanil-midazolam versus sufentanil-midazolam pour la sédation prolongée en réanimation. Ann Fr Anesth Reanim 2005 May; 24 (5): 480-6
60. Wilhelm W, Wrobel M, Ketter R, et al. Remifentanil/propofol versus fentanyl/midazolam for ICU sedation [abstract no. A705]. Eur J Anaesthesiol 2004; 21 Suppl. 32
61. Akinci SB, Kanbak M, Guler A, et al. Remifentanil versus fentanyl for short-term analgesia-based sedation in mechanically ventilated postoperative children. Paediatr Anaesth 2005 Oct; 15 (10): 870-8.
62. Stoppa F, Perrotta D, Tomasello C, et al. Low dose remifentanyl infusion for analgesia and sedation in ventilated newborns. Minerva Anestesiol 2004 Nov; 70 (11): 753-61
63. Andel H, Felfernig M, Knabl J, et al. Erste erfahrungen mit der langzeitanwendung von remifentanil auf der intensivpflegestation für brandverletzte. Anästh Intensivmed 2000; 41: 674-8
64. Tipps LB, Coplin WM, Murry KR, et al. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurgery 2000 Mar; 46 (3): 596-602
65. Müllejans B, Matthey T, Schill M, et al. Pharmacoeconomic evaluation of sedation with remifentanil/propofol versus midazolam/fentanyl in the intensive care unit [abstract no. DN4 plus oral presentation]. 8th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6-8; Florence
66. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998 Sep 15; 129 (6): 433-40
67. Rello J, Paiva JA, Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001 Sep; 120 (3): 955-70
68. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31 (5): 1312-7
69. Jacobi J, Fraser GL, Coursin DB, et al. Clincial practice guidelines for the sustained use of sedatives and analgesics in the critically ill patient. Crit Care Med 2002; 30 (1): 119-41
70. Samuelson KA, Larsson S, Lundberg D, et al. Intensive care sedation of mechanically ventilated patients: a national Swedish survey. Intensive Crit Care Nurs 2003 Dec; 19 (6): 350-62
71. Park G. Improving sedation and analgesia in the critically ill. Minerva Anestesiol 2002; 68 (6): 505-12
72. Malbrain M. Remifentanil use in the ICU: a health economic viewpoint. ICU Management 2005; 5 (2): 22-4
73. Liu LL, Gropper MA. Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection. Drugs 2003; 63 (8): 755-67
74. Cohen J, Royston D. Remifentanil. Curr Opin Crit Care 2001 Aug; 7 (4): 227-31
75. MacIntyre NR, Cook DJ, Ely EW, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001 Dec; 120 (6 Suppl.): 375-95S
76. Wolf AR, Potter F. Propofol infusion in children: when does an anesthetic tool become an intensive care liability? Paediatr Anaesth 2004 Jun; 14 (6): 435-8
77. Holzki J, Arnig C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: a case report. Paediatr Anaesth 2004 Mar; 14 (3): 265-70
78. Annane D, Bellissant E, Cavaillon J-M. Septic shock. Lancet 2005 Jan 1; 365: 63-78
79. Vender JS, Szokol JW, Murphy GS, et al. Sedation, analgesia, and neuromuscular blockade in sepsis: an evidence-based review. Crit Care Med 2004; 32 (11 Suppl.): S554-61